Rationale for triple-combination therapy for management of high blood pressure
- PMID: 21054774
- PMCID: PMC8816471
- DOI: 10.1111/j.1751-7176.2010.00360.x
Rationale for triple-combination therapy for management of high blood pressure
Abstract
The goals of antihypertensive therapy include optimal reduction in blood pressure (BP) while providing a favorable tolerability profile that promotes long-term adherence to treatment. For most patients with hypertension, these treatment goals cannot be achieved with monotherapy. When instituted early, however, combination therapy results in more rapid control of BP. This approach may facilitate improvements in long-term clinical outcomes, compared with more traditional and time-consuming stepped care and add-on algorithms for the management of hypertension. This review summarizes the rationale behind combination therapy, specifically triple-combination therapy, and discusses which combinations are most likely to result in better BP control, fewer side effects, and reduced risk of target organ damage. Supporting evidence from recent triple-combination therapy trials also is included in the review. Finally, the role of single-pill (fixed-dose) combination therapy in enhancing patient adherence is also discussed.
© 2010 Wiley Periodicals, Inc.
Similar articles
-
Using fixed-dose combination therapies to achieve blood pressure goals.Clin Drug Investig. 2008;28(11):713-34. doi: 10.2165/00044011-200828110-00005. Clin Drug Investig. 2008. PMID: 18840014 Review.
-
Optimizing the Management of Uncontrolled Hypertension: What do Triple Fixed-Dose Drug Combinations Add?Curr Vasc Pharmacol. 2017;16(1):61-65. doi: 10.2174/1570161115666170414115301. Curr Vasc Pharmacol. 2017. PMID: 28413969 Review.
-
New approach to blood pressure control: Triple combination pill.Trends Cardiovasc Med. 2020 Feb;30(2):72-77. doi: 10.1016/j.tcm.2019.03.002. Epub 2019 Mar 14. Trends Cardiovasc Med. 2020. PMID: 30926237 Review.
-
Management of hypertension with fixed-dose triple-combination treatments.Ther Adv Cardiovasc Dis. 2013 Oct;7(5):246-59. doi: 10.1177/1753944713498638. Epub 2013 Aug 14. Ther Adv Cardiovasc Dis. 2013. PMID: 23945906 Review.
-
Adhering to the principles of clinical pharmacology - the correct fixed combinations of antihypertensive drugs.Expert Rev Clin Pharmacol. 2018 Feb;11(2):165-170. doi: 10.1080/17512433.2018.1412826. Epub 2017 Dec 6. Expert Rev Clin Pharmacol. 2018. PMID: 29192802 Review.
Cited by
-
Differential treatment of hypertension by primary care providers and hypertension specialists in a barber-based intervention trial to control hypertension in Black men.Am J Cardiol. 2013 Nov 1;112(9):1421-6. doi: 10.1016/j.amjcard.2013.07.004. Epub 2013 Aug 23. Am J Cardiol. 2013. PMID: 23978276 Free PMC article. Clinical Trial.
-
Aliskiren, amlodipine and hydrochlorothiazide triple combination for hypertension.Expert Rev Cardiovasc Ther. 2012 Mar;10(3):293-303. doi: 10.1586/erc.12.7. Expert Rev Cardiovasc Ther. 2012. PMID: 22390800 Free PMC article. Review.
-
Triple combination therapy in hypertension: the antihypertensive efficacy of treatment with perindopril, amlodipine, and indapamide SR.Clin Drug Investig. 2014 Oct;34(10):701-8. doi: 10.1007/s40261-014-0223-0. Clin Drug Investig. 2014. PMID: 25212574
-
Medication compliance and clinical outcomes of fixed-dose combinations vs free combinations of an angiotensin II receptor blocker and a calcium channel blocker in hypertension treatment.J Clin Hypertens (Greenwich). 2017 Oct;19(10):983-989. doi: 10.1111/jch.13035. Epub 2017 May 30. J Clin Hypertens (Greenwich). 2017. PMID: 28560786 Free PMC article.
-
Fixed and Low-Dose Combinations of Blood Pressure-Lowering Agents: For the Many or the Few?Drugs. 2019 Nov;79(17):1831-1837. doi: 10.1007/s40265-019-01209-7. Drugs. 2019. PMID: 31602564 Review.
References
-
- Duprez DA. Does it matter how you lower blood pressure in patients with uncomplicated hypertension? Weighing the evidence. Curr Atheroscler Rep. 2007;9:352–358. - PubMed
-
- Lewington S, Clarke R, Qizilbash N, et al. Age‐specific relevance of usual blood pressure to vascular mortality: a meta‐analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903–1913. - PubMed
-
- Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood‐pressure‐lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists’ Collaboration. Lancet. 2000;356:1955–1964. - PubMed
-
- Ogden LG, He J, Lydick E, et al. Long‐term absolute benefit of lowering blood pressure in hypertensive patients according to the JNC VI risk stratification. Hypertension. 2000;35:539–543. - PubMed
-
- Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206–1252. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical